All In Biotech

Drug Trial Radar · NCT06806033

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab Monotherapy and Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Mar 5, 2025

Primary completion

Jul 31, 2029

Study completion Jul 31, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort A), and for glofitamab monotherapy (Cohort B) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.

Conditions

  • Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma

Interventions

  • ObinutuzumabDrug

    Participants will receive intravenous (IV) obinutuzumab 7 days prior to the first dose of glofitamab.

  • GlofitamabDrug

    Participants will receive IV glofitamab, both in combination with gemcitabine and oxaliplatin and as monotherapy, for up to 12 cycles (cycle length = 21 days).

  • GemcitabineDrug

    Participants will receive IV gemcitabine in combination with glofitamab and oxaliplatin for up to 8 cycles (cycles length = 21 days).

  • OxaliplatinDrug

    Participants will receive IV oxaliplatin in combination with glofitamab and gemcitabine for up to 8 cycles (cycle length = 21 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Cytokine Release Syndrome (CRS)Time frame: Up to approximately 5 years

Locations

53 sites in 7 countries. Site status is shown where the registry gives one.

  • Alaska Oncology & Hematology, LLC

    Anchorage, Alaska · Recruiting

  • Community Cancer Institute (CCI)

    Clovis, California · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • Los Angeles Cancer Network

    Glendale, California · Withdrawn

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials

    Panorama City, California · Recruiting

  • Zuckerberg San Francisco General Hospital

    San Francisco, California · Recruiting

  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente

    Torrance, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Aurora, Colorado · Recruiting

  • North Florida/ South Georgia VA Medical Center

    Gainesville, Florida · Withdrawn

  • Mount Sinai Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • St Luke?s Cancer Institute

    Boise, Idaho · Recruiting

  • Cancer Care Specialists of Central Illinois

    Swansea, Illinois · Recruiting

  • Mission Blood and Cancer - MercyOne Cancer Center

    Waukee, Iowa · Recruiting

  • University of Kentucky - Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Mary Bird Perkins Cancer Ctr

    Baton Rouge, Louisiana · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • Corewell Health

    Grand Rapids, Michigan · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • New York Oncology Hematology, P.C.

    Albany, New York · Recruiting

  • Hematology Oncology Associates of Central New York

    East Syracuse, New York · Recruiting

  • Oncology Associates of Oregon, P.C

    Eugene, Oregon · Recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Recruiting

  • Providence St. Vincent Medical Center

    Portland, Oregon · Recruiting

  • Tennessee Oncology

    Chattanooga, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Baylor Scott & White Health

    Temple, Texas · Recruiting

  • Texas Oncology - Gulf Coast

    The Woodlands, Texas · Recruiting

  • Texas Oncology- Northeast Texas

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates - Virginia Beach

    Virginia Beach, Virginia · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Recruiting

  • Epworth Hospital

    East Melbourne, Victoria, Australia · Recruiting

  • Arthur J.E. Child Comprehensive Cancer Center

    Calgary, Alberta, Canada · Recruiting

  • CancerCare Manitoba (CCMB)

    Winnipeg, Manitoba, Canada · Recruiting

  • CHU de Grenoble

    La Tronche, France · Recruiting

  • Chu de Montpellier-St Eloi

    Montpellier, France · Recruiting

  • CHU de Bordeaux

    Pessac, France · Recruiting

  • CHU DE RENNES - CHU Pontchaillou

    Rennes, France · Withdrawn

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.